Brainstorm Cell Therapeutics Raises $2 Million in Strategic Placements

The funding will support the company's regulatory and clinical development initiatives for its NurOwn therapy.

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

Brainstorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, has announced that it has entered into a second definitive agreement for an additional $1 million strategic private placement, bringing the total capital raised in February 2026 to $2 million. The financing is expected to reinforce a stable valuation for the company and provide the near-term resources required to advance its immediate regulatory and clinical objectives.

Why it matters

The additional funding will allow Brainstorm to focus on the preparatory work and strategic funding requirements for its planned Phase 3b clinical trial of its lead investigational therapy, NurOwn, for the treatment of amyotrophic lateral sclerosis (ALS). The company believes this capital influx, combined with its disciplined management of legacy liabilities, significantly extends its operational runway.

The details

The common stock was priced at $0.60 per share, closely aligned with recent market performance. The placement includes 120% warrant coverage with an exercise price of $1.00 per share, serving as a significant "valuation target" for institutional partners. The investment is funded in staged installments, allowing for up to eight payments, providing the company with consistent and predictable cash flows to support near-term operational objectives.

  • The financing was announced on February 26, 2026.

The players

Brainstorm Cell Therapeutics Inc.

A leading developer of adult stem cell therapies for neurodegenerative diseases, and the company behind the NurOwn technology platform.

Chaim Lebovits

President and CEO of Brainstorm Cell Therapeutics Inc.

Got photos? Submit your photos here. ›

What they’re saying

“We believe that securing a cumulative $2 million in a single week establishes a floor for our valuation and reflects the market's growing confidence in our trajectory.”

— Chaim Lebovits, President and CEO (PRNewswire)

What’s next

The company intends to use the proceeds for working capital and general corporate purposes, including the support of its ongoing regulatory and clinical development initiatives for the NurOwn therapy.

The takeaway

The additional $2 million in strategic funding will enable Brainstorm to advance its NurOwn therapy, a promising investigational treatment for neurodegenerative diseases like ALS, and support the company's preparatory work for a planned Phase 3b clinical trial.